![]() ![]() The changes had no impact to amounts previously reported. During the fourth quarter of 2022, the Company retitled its revenue categories from product revenue and service revenue to medication revenue and technology-enabled solutions revenue, respectively, in its consolidated statements of operations and notes to the consolidated financial statements. We are in a strong position as we enter 2023, and I am extremely proud of our team members and what we have accomplished over the last year as we continue to make positive impacts on patient care for our customers," said Brian Adams, President and Interim Chief Executive Officer.Īdjusted net loss from continuing operationsĪdjusted EBITDA from continuing operationsĪll comparisons, unless otherwise noted, are to the three months ended December 31, 2021, and reflect continuing operations. These include strengthening our management team, refreshing our Board of Directors, and divesting two non-core businesses, which is allowing the Company to refocus its vision and better deliver consistent execution of our financial and strategic objectives. "Since the leadership changes announced last September, we have taken a number of transformational steps to reposition TRHC for long-term success and profitable growth. Full year 2022 GAAP net loss and adjusted EBITDA from continuing operations of $77.3 million and $9.3 million, respectively. ![]() Full year 2022 revenue from continuing operations of $299.5 million, representing a 15% increase versus the prior year.Fourth quarter GAAP net loss and adjusted EBITDA from continuing operations of $18.4 million and $4.1 million, respectively.Fourth quarter revenue from continuing operations of $82.7 million, representing a 20% increase versus the prior year fourth quarter.Highlights from fourth quarter and full year 2022 include: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |